Evidence-based treatment for schizophrenia

Psychiatric Clinics of North America

Volumn 26, Issue 4, 2003, Pages 939-954

  Lehman, Anthony F ^a,b   Buchanan, Robert W ^a,b   Dickerson, Faith B ^c   Dixon, Lisa B ^a,b   Goldberg, Richard ^a   Green Paden, Lisa ^a   Kreyenbuhl, Julie ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b Veterans Administration VISN 5 Mental Illness Research Education and Clinical Center   (United States)

^c SHEPPARD PRATT HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; CYCLOSERINE; DEXTRO SERINE; FLUPHENAZINE; FLUVOXAMINE; GLUTAMATE RECEPTOR; GLUTAMINE DERIVATIVE; GLYCINE; HALOPERIDOL; LITHIUM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE;

BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; DEPRESSION; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DYSPHORIA; EMPLOYMENT; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; FAMILY THERAPY; FUNCTIONAL DISEASE; GROUP THERAPY; HEALTH PROGRAM; HUMAN; INSTITUTIONALIZATION; MENTAL HEALTH SERVICE; NEUROLOGIC DISEASE; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PATIENT EDUCATION; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOSOCIAL CARE; RATING SCALE; RELAPSE; REVIEW; SCHIZOPHRENIA; SKILL; SOCIAL ASPECT; SUICIDAL BEHAVIOR; SYMPTOM; TRAINING; TREATMENT INDICATION; VIOLENCE;

EID: 0346733314     PISSN: 0193953X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0193-953X(03)00070-4     Document Type: Review

References (86)

1. Norquist GS, Regier DA, Rupp A. Estimates of the cost of treating people with schizophrenia: contributions from data from epidemiologic surveys. In: Moscarelli M, Rupp A, Sartorius N, editors. Handbook of mental health economics and health policy. volume 1. New York: John Wiley & Sons; 1996. p. 95-102.
2. Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020; global burden of disease study. Lancet 1997;349:1498-504.
3. Lehman AF, Steinwachs DS. Coinvestigators of the PORT Project. Translating research into practice: the schizophrenia patient outcomes research team (PORT) treatment recommendations. Schizophr Bull 1998a;24:1-10.
4. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Washington (DC): American Psychiatric Association Press; 1997.
5. Veterans Health Administration. Clinical practice guidelines for the management of psychosis. Washington (DC), 1998.
6. Miller AL, Chiles JA, Chiles JK, Crismon MD, Shon SP, Rush AJ. The TMAP Schizophrenia Algorithms. J Clin Psychiatry 1999;60(10):649-57.
7. Frances A, Docherty J, Kahn DA. The expert consensus guideline series: treatment of schizophrenia. J Clin Psychiatry 1996;57:1-58.
8. Attkisson C, Cook J, Karno M, Lehman A, McGlashan TH, Meltzer HY, et al. Clinical services research. Schizophr Bull 1992;18:561-626.
9. Dixon L, Lehman A, Levine J. Conventional antipsychotic medications for schizophrenia. Schizophr Bull 1995;21(4):567-78.
10. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, et al. Canadian multi-center placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13(1):25-40.
11. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151(6):825-35.
12. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multinational, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry 1995;166(6):712-26.
13. Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Kruegar JA, Tamura RN, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154(4):457-65.
14. Copolov DL, Link CG, Kowalcyk B. A multi-centre, double-blind, randomized comparison of quetiapine (ICI 204,636, "Seroquel") and haloperidol in schizophrenia. Psychol Med 2000;30(1):95-105.
15. Purdon SE, Jones BD, Stip E, Labelle A, Addington D, David SR, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry 2000;57(3):249-58.
16. Csernansky JG, Mahmoud R, Brenner RA. Comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346(1):16-22.
17. Hirsch SR, Kissling W, Bauml J, Power A, O'Connor R. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry 2002;63(6):516-23.
18. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63(9):763-71.
19. Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med 1997;337(12):809-15.
20. Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT Jr. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry 1998;155(6):751-60.
21. Kane JM, Marder SR, Schooler NR, Wirshing WC, Umbricht D, Baker RW, et al. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch Gen Psychiatry 2001;58(10):965-72.
22. Bondolfi GH, Dufour H, Patris M, May JP, Billeter U, Eap CB, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am J Psychiatry 1998;155(4):499-504.
23. Breier AF, Malhotra AK, Su TP, Pinals DA, Elman I, Adler CM, et al. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, Parkinsonian side effects, and neuroendocrine response. Am J Psychiatry 1999;156(2):294-8.
24. Azorin JM, Spiegel R, Remington G, Vanelle JM, Pere JJ, Giguere M, et al. A doubleblind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am J Psychiatry 2001;158(8):1305-13.
25. Volavka JP, Czobor P, Sheitman B, Lindenmeyer JP, Citrome L, McEvoy JP, et al. Clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002;159:255-62.
26. Emsley RA, Raniwalla J, Bailey PJ, Jones AM. A comparison of the effects of quetiapine ("seroquel") and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Intl Clin Psychopharmacol 2000;15(3):121-31.
27. Conley RR, Tamminga CA, Kelly DL, Richardson CM. Treatment resistant schizophrenic patients respond to clozapine after olanzapine nonresponse. Biol Psychiatry 1999;46:73-7.
28. Essock SM, Hargreaves WA, Covell NH, Goethe J. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol Bull 1996;32(4):683-97.
29. Conley RR, Love RC, Kelly DL, Bartko JJ. Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. Am J Psychiatry 1999b;156:863-8.
30. Johns C, Thompson J. Adjunctive treatments in schizophrenia: pharmacotherapies and electroconvulsive therapy. Schizophr Bull 1995;21(4):607-19.
31. Hogarty GE, McEvoy JP, Ulrich RF, DiBarry AL, Bartone P, Cooley S, et al. Pharmacotherapy of impaired affect in recovering schizophrenic patients. Arch Gen Psychiatry 1995;52(1):29.
32. Goff DC, Midha KK, Sarid-Segal O, Hubbard JW, Amico E. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology (Berl) 1995;117(4):417-23.
33. Lee MS, Kim YK, Lee SK, Suh KY. A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia. J Clin Psychopharmacol 1998;18(5):399-403.
34. Siris S, Pollack S, Bermanzohn P, Stronger R. Adjunctive imipramine for a broader group of postpsychotic depressions in schizophrenia. Schizophr Res 2000;44(3):187-92.
35. Schulz SC, Thompson PA, Jacobs M, Ninan PT, Robinson D, Weiden PJ, et al. Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients. J Clin Psychiatry 1999;60(6):366-72.
36. Nachshoni T, Levin Y, Levy A, Kritz A, Neumann M. A double-blind trial of carbamazepine in negative symptom schizophrenia. Biol Psychiatry 1994;35(1):22-6.
37. Dixon L, Lehman A. Family interventions for schizophrenia. Schizophr Bull 1995;21:631-43.
38. Dixon L, Adams C, Lucksted A. Update on family psychoeducation for schizophrenia. Schizophr Bull 2000;26(1):5-20.
39. Hogarty GE, Anderson CM, Reiss DJ, Kornblith SJ, Greenwald DP, Ulrich RF, et al. Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia: Two-year effects of a controlled study on relapse and adjustment. Arch Gen Psychiatry 1991;48:340-7.
40. McFarlane WR, Lukens E, Link B, Dushay R, Deakins SA, Newmark M, et al. Multiple family group and psychoeducation in the treatment of schizophrenia. Arch Gen Psychiatry 1995;52:679-87.
41. Stein LI, Test MA. Alternative to mental hospital treatment: I. Conceptual model, treatment program, and clinical evaluation. Arch Gen Psychiatry 1980;37:392-7.
42. Scott J, Dixon L. Assertive community treatment and case management. Schizophr Bull 1995;21(4):657-68.
43. Mueser KT, Bond GR, Drake RE, Resnick SG. Models of community care for severe mental illness: a review of research on case management. Schizophr Bull 1998;42(1):37-74.
44. Dickerson FB. Cognitive behavioral psychotherapy for schizophrenia: a review of recent empirical studies. Schizophr Res 2000;43:71-90.
45. Goldberg TE, Greenberg RD, Griffin SJ, Gold JM, Kleinman JE, Pickar D, et al. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry 1993;162:43-8.
46. Buchanan RW, Brandes M, Breier A. Treating negative symptoms: pharmacological strategies. In: Breier A, editor. The new pharmacotherapy of schizophrenia. Washington (DC): American Psychiatric Press; 1996. p. 179-204.
47. Silver H. Fluvoxamine as an adjunctive agent in schizophrenia. CNS Drug Rev 2001;7:283-304.
48. Heresco-Levy, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 1999;56:29-36.
49. Goff DC, Tsai G, Levitt J, Amico E, McCarley R. A placebo-controlled trial of d-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 1999;56:21-7.
50. Tsai GE, Yang P, Chung LC, Tsai IC, Tsai CW, Coyle JT. D-serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry 1999;156:1822-5.
51. Rector NA, Beck AT. Cognitive behavioral therapy for schizophrenia: an empirical review. J Nerv Ment Dis 2001;189(5):278-87.
52. Dyck DG, Short RA, Hendry M, Norell D, Myers M, Patterson T, et al. Management of negative symptoms among patients with schizophrenia attending multiple-family groups. Psychiatr Serv 2000;51:513-9.
53. Siris SG, Bermanzohn PC, Mason SE, Shuwall MA. Maintenance imipramine therapy for secondary depression in schizophrenia. A controlled trial. Arch Gen Psychiatry 1994;51(2):109-15.
54. Addington D, Addington J, Patten S, Remington G, Moamai J, Labelle A, et al. Doubleblind, placebo-controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia. J Clin Psychopharmacol 2002;22(1):20-5.
55. Levinson DF, Umapathy C, Musthaq M. Treatment of schizoaffective disorder and schizophrenia with mood symptoms. Am J Psychiatry 1999;156:1138-48.
56. Citrome L, Volavka J, Czobor P, Sheitman B, Lindenmayer JP, McEvoy J, et al. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatr Serv 2001;52(11):1510-4.
57. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995;152(2):183-90.
58. Spivak B, Roitman S, Vered Y, Mester R, Graff E, Talmon Y, et al. Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine. Clin Neuropharmacol 1998;21(4):245-50.
59. Ciapparelli A, Dell'Osso L, Pini S, Chiavacci MC, Fenzi M, Cassano GB. Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study. J Clin Psychiatry 2000;61(5):329-34.
60. Walker AM, Lanza LL, Arellano F, Rothman KJ. Mortality in current and former users of clozapine. Epidemiology 1997;8(6):671-7.
61. Sernyak MJ, Desai R, Stolar M, Rosenheck R. Impact of clozapine on completed suicide. Am J Psychiatry 2001;158(6):931-7.
62. Reid WH, Mason M, Hogan T. Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder. Psychiatr Serv 1998;49(8):1029-33.
63. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, et al. International Suicide Prevention Trial Study Group. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003;60:82-91.
64. Medalia A, Gold J, Merriam A. The effects of neuroleptics on neuropsychological test results of schizophrenics. Arch Clin Neuropsychol 1988;3:249-71.
65. Blyler CR, Gold JM. Cognitive effects of typical antipsychotic treatment: another look. In: Sharma T, Harvey P, editors. Cognition in schizophrenia. New York: Oxford University Press; 2000. p. 241-65.
66. Harvey PD, Keefe RSE. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 2001;158:176-84.
67. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999;25(2):233-55.
68. Keefe RSE, Silva SG, Perkins DO, Lieberman JA. The effects of atypical drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 1999;25(2):201-22.
69. Buchanan RW, Holstein C, Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry 1994;36(11):717-25.
70. Hoff AL, Faustman WO, Wieneke M, Espinoza S, Costa M, Wolkowitz O, et al. The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients. Neuropsychopharmacology 1996;15(4):361-9.
71. Grace J, Bellus SB, Raulin ML, Herz MI, Priest BL, Brenner V, et al. Long-term impact of clozapine and psychosocial treatment on psychiatric symptoms and cognitive functioning. Psychiatr Serv 1996;47:41-4.
72. Galletly CA, Clark CR, McFarlane AC, Weber DL. The effect of clozapine on the speed and accuracy of information processing in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2000;24(8):1329-38.
73. Green MF, Marshall BD Jr, Wirshing WC, Ames D, Marder SR, McGurk S, et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Amer J Psychiatry 1997;154(6):799-804.
74. Kern RS, Green MF, Marshall BD Jr, Wirshing WC, Wirshing D, McGurk S, et al. Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients. Biol Psychiatry 1998;44(8):726-32.
75. Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002;159:1018-28.
76. Green MF, Marder SR, Glynn SM, McGurk SR, Wirshing WC, Wirshing DA, et al. The neurocognitive effects of low-dose haloperidol: A two-year comparison with risperidone. Biol Psychiatry 2002;51:972-8.
77. Wykes T, van der Gaag M. Is it time to develop a new cognitive therapy for psychosis-cognitive remediation therapy (CRT)? Clin Psychol Rev 2001;21(8):1227-56.
78. Anthony WA, Rogers ES, Cohen M, Davies RR. Relationship between psychotic symptomatology, work skills, and future vocational performance. Psychiatr Serv 1995;46:353-8.
79. Carpenter WT, Buchanan RW. Schizophrenia. N Engl J Med 1994;330:681-90.
80. Bond G, Drake RE, Becker D, Mueser K. Effectiveness of psychiatric rehabilitation approaches for employment of people with severe mental illness. Journal of Disability and Policy Studies 1999;10:18-52.
81. Bond G, Drake R, Mueser KT, Becker D. An update on supported employment for people with severe mental illness. Psychiatr Serv 1997;48:335-46.
82. Lehman AF. Vocational rehabilitation in schizophrenia. Schizophr Bull 1995;21(4):645-56.
83. Heinssen RK, Kiberman RP, Koplelwicz M. Psychosocial skills training for schizophrenia: lessons from the laboratory. Schizophr Bull 2000;26:21-46.
84. Lehman AF, Steinwachs DS and the survey coinvestigators of the PORT Project. Patterns of usual care for schizophrenia: initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey. Schizophr Bull 1998;24(1):11-20.
85. Young AS, Sullivan G, Burnam A, Brook RH. Measuring the quality of outpatient treatment for schizophrenia. Arch Gen Psychiatry 1998;55(7):611-7.
86. Carpenter Jr. WT, Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 1988;145:578-83.